Skip to main content
Equibles
TMDX logo

TMDX · TransMedics Group, Inc. · Earnings Call Transcripts & Audio

Track TMDX — free

Use TMDX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TMDX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$88.75 +2.89 (+3.37%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$2.85B
Shares
34.68M

TransMedics Group, Inc. Earnings Call Transcripts

Quarterly earnings calls for TransMedics Group, Inc. (TMDX), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲378.3% $25.68M −$7.43M '22 Q3 22-11-03 ▲224.5% $31.38M −$6.72M '22 Q4 23-02-22 ▲161.7% $41.55M −$2.64M '23 Q1 23-05-01 ▲155.7% $52.47M −$1.00M '23 Q2 23-08-03 ▲158.7% $66.43M −$25.42M '23 Q3 23-11-06 ▲158.7% $81.17M $4.03M '23 Q4 24-02-26 ▲133.1% $96.85M $12.20M '24 Q1 24-04-30 ▲117.9% $114.31M $12.19M '24 Q2 24-07-31 ▲63.7% $108.76M $4.22M '24 Q3 24-10-28 ▲49.8% $121.62M $6.86M '24 Q4 25-02-27 ▲48.2% $143.54M $25.68M '25 Q1 25-05-08 ▲37.7% $157.37M $34.91M '25 Q2 25-07-30 ▲32.2% $143.82M $24.32M '25 Q3 25-10-29 ▲32.2% $160.76M $105.38M '25 Q4 26-02-24 ▲21.2% $173.93M $7.32M '26 Q1 26-05-05 LATEST ▲20.7% $189.95M $14.68M '26 Q2 26-08-04
Conference
Investor event
2026-08-11
TransMedics Group, Inc. (TMDX) August 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-04
TransMedics Group, Inc. (TMDX) Q2 2026 Earnings Call
Revenue
$189.95M
▲ 20.7% YoY
Diluted EPS
$0.41
▼ 55.4% YoY
Gross margin
59.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-02
TransMedics Group, Inc. (TMDX) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-05
TransMedics Group, Inc. (TMDX) Q1 2026 Earnings Call Transcript
Confident tone ENHANCE Heart and DENOVO Lung Trials CHOPS Cold Storage Device Full-Year Revenue Guidance
Revenue
$173.93M
▲ 21.2% YoY
Diluted EPS
$0.20
▼ 71.4% YoY
Gross margin
58.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
TransMedics Group, Inc. (TMDX) Q4 2025 Earnings Call Transcript
Confident tone 2026 Margin / Investment Guidance OPO / CMS Regulatory Landscape ENHANCE Heart and DENOVO Lung Clinical Programs
Revenue
$160.76M*
▲ 32.2% YoY
Gross margin
58.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-29
TransMedics Group, Inc. (TMDX) Q3 2025 Earnings Call Transcript
Confident tone Competitive Landscape / OrganOx Acquisition International / Italy NOP Expansion Seasonality and Market Softness
Revenue
$143.82M
▲ 32.2% YoY
Diluted EPS
$0.66
▲ 450% YoY
Gross margin
58.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
TransMedics Group, Inc. (TMDX) Q2 2025 Earnings Call Transcript
Confident tone Summer seasonality and Q3 outlook / guidance National Transplant Modernization initiative and tariffs Kidney OCS platform and international NOP expansion
Revenue
$157.37M
▲ 37.7% YoY
Diluted EPS
$0.92
▲ 162.9% YoY
Gross margin
61.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
TransMedics Group, Inc. (TMDX) Q1 2025 Earnings Call Transcript
Confident tone OCS NOP Commercial Growth Next-Gen OCS Heart and Lung Clinical Programs 2025 Outlook and Guidance
Revenue
$143.54M
▲ 48.2% YoY
Diluted EPS
$0.70
▲ 100% YoY
Gross margin
61.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
TransMedics Group, Inc. (TMDX) Q4 2024 Earnings Call Transcript
Confident tone Q4 and Full Year 2024 Results 2025 Financial Guidance Transplant Logistics / Aviation Fleet Expansion
Revenue
$121.62M*
▲ 49.8% YoY
Gross margin
59.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-28
TransMedics Group, Inc. (TMDX) Q3 2024 Earnings Call Transcript
Positive tone Revenue growth and mix (U.S. vs OUS) Competitive dynamics (NRP) and pricing International / OUS expansion
Revenue
$108.76M
▲ 63.7% YoY
Diluted EPS
$0.12
Gross margin
55.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
TransMedics Group, Inc. (TMDX) Q2 2024 Earnings Call Transcript
Confident tone Revenue Growth and Financial Performance Transplant Logistics Network Expansion Clinical Pipeline (Lung and Heart Programs)
Revenue
$114.31M
▲ 117.9% YoY
Diluted EPS
$0.35
Gross margin
60.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-04-30
TransMedics Group, Inc. (TMDX) Q1 2024 Earnings Call Transcript
Confident tone NOP and transplant logistics / aviation fleet OCS clinical programs and pipeline Revenue growth and guidance raise
Revenue
$96.85M
▲ 133.1% YoY
Diluted EPS
$0.35
Gross margin
61.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-26
TransMedics Group, Inc. (TMDX) Q4 2023 Earnings Call Transcript
Confident tone National OCS transplant program (NOP) TransMedics logistics services Gross margin trajectory
Revenue
$81.17M*
▲ 158.7% YoY
Gross margin
59.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-06
TransMedics Group, Inc. (TMDX) Q3 2023 Earnings Call Transcript
Revenue
$66.43M
▲ 158.7% YoY
Diluted EPS
$-0.78
Gross margin
61.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
TransMedics Group, Inc. (TMDX) Q2 2023 Earnings Call Transcript
Revenue
$52.47M
▲ 155.7% YoY
Diluted EPS
$-0.03
Gross margin
70.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-01
TransMedics Group, Inc. (TMDX) Q1 2023 Earnings Call Transcript
Revenue
$41.55M
▲ 161.7% YoY
Diluted EPS
$-0.08
Gross margin
69.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-22
TransMedics Group, Inc. (TMDX) Q4 2022 Earnings Call Transcript
Revenue
$31.38M*
▲ 224.5% YoY
Gross margin
66.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
TransMedics Group, Inc. (TMDX) Q3 2022 Earnings Call Transcript
Revenue
$25.68M
▲ 378.3% YoY
Diluted EPS
$-0.25
Gross margin
70.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-01
TransMedics Group, Inc. (TMDX) Q2 2022 Earnings Call Transcript
Revenue
$20.52M
▲ 151.1% YoY
Diluted EPS
$-0.41
Gross margin
69.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
TransMedics Group, Inc. (TMDX) Q1 2022 Earnings Call Transcript
Revenue
$15.88M
▲ 125.2% YoY
Diluted EPS
$-0.38
Gross margin
76.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
TransMedics Group, Inc. (TMDX) Q4 2021 Earnings Call Transcript
Revenue
$9.67M*
▲ 26.8% YoY
Gross margin
72.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
TransMedics Group, Inc. (TMDX) Q3 2021 Earnings Call Transcript
Revenue
$5.37M
▼ 24.3% YoY
Diluted EPS
$-0.47
Gross margin
70.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
TransMedics Group, Inc. (TMDX) Q2 2021 Earnings Call Transcript
Revenue
$8.17M
▲ 141% YoY
Diluted EPS
$-0.39
Gross margin
68.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-04
TransMedics Group, Inc. (TMDX) Q1 2021 Earnings Call Transcript
Revenue
$7.05M
▼ 6.3% YoY
Diluted EPS
$-0.29
Gross margin
68.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-02
TransMedics Group, Inc. (TMDX) Q4 2020 Earnings Call Transcript
Revenue
$7.63M
▲ 25.9% YoY
Gross margin
63.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
TransMedics Group, Inc. (TMDX) Q3 2020 Earnings Call Transcript
Revenue
$7.09M
▼ 1.6% YoY
Diluted EPS
$-0.19
Gross margin
71.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
TransMedics Group, Inc. (TMDX) Q2 2020 Earnings Call Transcript
Revenue
$3.39M
▼ 40.2% YoY
Diluted EPS
$-0.36
Gross margin
56.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-04-13
TransMedics Group, Inc. (TMDX) Q1 2020 Earnings Call Transcript
Revenue
$7.53M
▲ 61% YoY
Diluted EPS
$-0.42
Gross margin
64.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-04
TransMedics Group, Inc. (TMDX) Q4 2019 Earnings Call
Revenue
$6.06M
▲ 70.9% YoY
Gross margin
61.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–29 of 29 earnings calls
Key facts CIK 1756262 CUSIP 89377M109 13F (30d) 14 filings 13 filers Visit website Investor relations